Awareness, knowledge, and behaviour of Jordanian public regarding misuse and overuse of proton pump inhibitors
Main Article Content
Keywords
proton pump inhibitors (PPIs/PPI), awareness, knowledge, behaviour web-based survey, Jordan
Abstract
Background: Proton pump inhibitors (PPIs) are frequently used for the treatment and prophylaxis of upper gastrointestinal tract disorders. PPIs are now frequently the first-choice treatment for people with diseases associated with acidity. Objectives: The aim of this study is to assess the awareness, knowledge, and behaviour of the Jordanian public regarding the misuse and overuse of proton pump inhibitors. Methodology: The survey was made with Google Forms and made available online through various social media channels. Using a practical sample technique and the snowball dissemination of the questionnaire, participants were recruited. Adulthood and residence in the Hashemite Kingdom of Jordan were requirements for inclusion. Results: A total of 418 participants responded and filled out the questionnaire, with an average age of 37.5 ± 14.2 years. almost one third experienced a GI disease, n = 115 (27.5%), but around half of the participants, 204 (48.8%), used at least one type of PPI. 88 (43.1%) of the participants who used the PPIs experienced vitamin B12 deficiency as the most frequent side effect. The knowledge score was calculated for participants; the overall knowledge score was very low (2.8/8); the lowest score was on the correct duration for PPI use (0.13/1). In the multivariate analysis, predictors of a higher score of knowledge were working in a medical field and a monthly income lower than 500 JD. Conclusion: Findings from this study demonstrated that the overall knowledge score for Jordanians was low, which indicates that the Jordanian public is unaware of the PPIs correct use and possible side effects. Hence, with the dramatic increase in PPIs use, educational initiatives and programs are required to enhance public knowledge, particularly among those with non-medical educational backgrounds and monthly income above 500 JD.
References
2. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. Journal of Neurogastroenterology and Motility. 2013;19(1):25.
3. Eid SM, Boueiz A, Paranji S, et al. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Internal Medicine. 2010;49(23):2561-8. https://doi.org/10.2169/internalmedicine.49.4064
4. Savarino V, Marabotto E, Zentilin P, et al. Proton pump inhibitors: use and misuse in the clinical setting. Expert review of clinical pharmacology. 2018;11(11):1123-34. https://doi.org/10.1080/17512433.2018.1531703
5. Makunts T, Alpatty S, Lee KC, et al. Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory. Scientific reports. 2019;9(1):1-10. https://doi.org/10.1038/s41598- 019-53622-3
6. Mazer-Amirshahi M. Rising rates of proton pump inhibitor prescribing in US emergency departments. Am J Emerg Med. 2014;32(6):618-22. https://doi.org/10.1016/j.ajem.2014.03.019
7. Simonso W. Implications of over-the-counter proton pump inhibitors for patient counseling by pharmacists. Am J Ther. 2013;20(6):676-84. https://doi.org/10.1097/mjt.0b013e318217a5d1
8. McCoul ED. Direct-To-Consumer Advertising of Over-the-Counter Sinonasal Remedies: A History of Mixed Messages. Laryngoscope. 2020;130(9):2114-19. https://doi.org/10.1002/lary.28366
9. Ladd AM. Potential costs of inappropriate use of proton pump inhibitors. Am J Med Sci. 2014;347(6):446-51. https://doi. org/10.1097/maj.0b013e31829f87d510. Raosoft I. Sample size calculator. Available from: https://www.raosoft com/samplesize. 2004.
11. Youth. Unicef.org. Accessed March 2, 2022. Available at: https://www.unicef.org/jordan/youth
12. Mosleh SM, Almalik MM. Illness perception and adherence to healthy behaviour in Jordanian coronary heart disease patients. European Journal of Cardiovascular Nursing. 2016;15(4):223-30. https://doi.org/10.1177/1474515114563885
13. Heidelbaugh JJ, Kim AH, Chang R, et al. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therapeutic Advances in Gastroenterology. 2012;5(4):219-32. https://doi.org/10.1177/1756283x12437358
14. Moriarty F, Cahir C, Bennett K, et al. Potentially inappropriate prescribing and its association with health outcomes in middle-aged people: a prospective cohort study in Ireland. BMJ open. 2017;7(10):e016562. https://doi.org/10.1136/ bmjopen-2017-016562
15. Eusebi LH, Rabitti S, Artesiani ML, et al. Proton pump inhibitors: risks of long‐term use. Journal of gastroenterology and hepatology. 2017;32(7):1295-302. https://doi.org/10.1111/jgh.13737
16. Nishtala PS, Soo L. Proton pump inhibitors utilisation in older people in New Zealand from 2005 to 2013. Intern Med J. 2015;45(6):624-9. https://doi.org/10.1111/imj.12757
17. Imhann F. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740-8. https://doi.org/10.1136/ gutjnl-2015-310376
18. Alqudah MA. Overuse of proton pump inhibitors for stress ulcer prophylaxis in Jordan. Int J Clin Pharmacol Ther. 2016;54(8):597- 602. https://doi.org/10.5414/cp202533
19. Souaid CK. Relevance of proton pump inhibitors prescriptions in a tertiary care hospital in Lebanon. Arab Journal of Gastroenterology. 2020;21(3):194-8. https://doi.org/10.1016/j.ajg.2020.07.008
20. Ntaios G. Evaluation of use of proton pump inhibitors in Greece. Eur J Intern Med. 2009;20(2):171-3. https://doi.org/10.1016/j. ejim.2007.10.020
21. Alhossan A. Attitude and knowledge of Saudi community pharmacists towards use of proton pump inhibitors. Saudi Pharm J. 2019;27(2):225-8. https://doi.org/10.1016/j.jsps.2018.11.002
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.